This article needs additional citations for verification. (September 2016) |
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Serc, others |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ~100%[1] |
Protein binding | <5%[1] |
Metabolism | Liver[1] |
Metabolites | • 2-(2-Aminoethyl)pyridine • 2-Pyridylacetic acid[1] |
Onset of action | <1 hour (peak)[2] |
Elimination half-life | 3.5 hours[3] |
Excretion | Urine: 91%[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.024.625 |
Chemical and physical data | |
Formula | C8H12N2 |
Molar mass | 136.198 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms. It was first registered in Europe in 1970 for the treatment of Ménière's disease, but current evidence does not support its efficacy in treating it.[4][5]